Droplex cMET Exon 14 Skipping Mutation Test

Detection of the Exon 14 Skipping on RNA level


In Non-small Cell Lung Cancer (NSCLC), cMET Exon 14 Skipping mutation is related with NSCLC-drug resistance. When MET Exon 14 skipping occurs, the MET pathway, which plays an important role in cell signaling, proliferation, and survival, is overstimulated and causes proliferation of cancer cells. The CE-IVD certified assay detects the Exon 14 Skipping on RNA level using Digital DropletTM Technology. This companion diagnostic test helps identify NSCLC cancer patients who are eligible for tailored treatment.

BIOTYPE is the exclusive distributor of the Droplex Test Series in Germany. Legal manufacturer of the kits is GENCURIX, Inc.


Exon 14: Exon 14-Skipping

Product specifications

  • Cat No.
  • CD007
  • Cancer type
  • Non-Small Cell Lung Cancer
  • Regulatory status
  • CE-IVD
  • Compatible sample type
  • RNA from FFPE tissue, RNA from whole blood
  • Mutation variants
  • Exon 14-Skipping
  • Kit size/reactions
  • 24 samples/kit (2 well-reactions/sample)
  • Platform
  • Digital DropletTM PCR


Instructions for Use / Handbooks
No items found.
Safety Data Sheets / Non-Hazardous Statements
No items found.
Non Hazardous Statements
No items found.
Technical Information
No items found.

Ordering Information

Droplex cMET Exon 14 Skipping Mutation Test

Kit size/reactions: 24 samples/kit (2 well-reactions/sample)
Cat. No.: CD007
Status: CE-IVD

Product Request